2014, June 12
D-Pharm’s DP-b99 Prevents Abnormal Neuronal Plasticity and Pathological Brain Reorganization.
2014, June 8
D-Pharm’s anti-epileptic drug DP-VPA is granted Fast Track Status by the Chinese Food and Drug Administration (CFDA)
2014, June 2
D-Pharm reports completion of the second dose tier in its Phase 2 clinical study of THR-18 in acute stroke patients treated with the thrombolytic drug tPA.
Therapeutic Focus & Market Size
Reports & Regulatory Announcements
Presentation & Factsheet
Advisors & Investors Contacts